US 11,865,212 B2
Systems and methods for targeted breast cancer therapies
Ghaleb Husseini, Sharjah (AE); Mohammad Al-Sayah, Sharjah (AE); and Amal Elsadig, Sharjah (AE)
Assigned to American University of Sharjah, Sharjah (AE)
Filed by American University of Sharjah, Sharjah (AE)
Filed on Dec. 11, 2020, as Appl. No. 17/119,001.
Application 17/119,001 is a continuation of application No. 16/159,550, filed on Oct. 12, 2018, granted, now 10,864,161.
Claims priority of provisional application 62/572,358, filed on Oct. 13, 2017.
Prior Publication US 2021/0113465 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/127 (2006.01); A61P 35/00 (2006.01); A61M 37/00 (2006.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61K 31/704 (2006.01); A61K 41/00 (2020.01)
CPC A61K 9/1271 (2013.01) [A61K 31/704 (2013.01); A61K 41/0028 (2013.01); A61K 47/6849 (2017.08); A61K 47/6855 (2017.08); A61K 47/6913 (2017.08); A61M 37/0092 (2013.01); A61P 35/00 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating cancer in a mammal, the method comprising:
delivering an actively targeted liposome to the mammal, the actively targeted liposome comprising:
a lipid bilayer forming a spherical shell, the spherical shell comprising an interior liposomal cavity, the lipid bilayer comprising cholesterol and polyethylene glycol,
a plurality of trastuzumab molecules linked to a surface of the actively targeted liposome, and
a chemotherapeutic drug, the chemotherapeutic drug comprising at least one of a hydrophilic chemotherapeutic drug contained within the interior liposomal cavity and a hydrophobic chemotherapeutic drug contained within the lipid bilayer of the actively targeted liposome; and
allowing the actively targeted liposome to circulate throughout a circulatory system of the mammal for a time sufficient to allow aggregation of a therapeutic quantity of actively targeted liposomes at a treatment area comprising a cancer;
applying ultrasound to the treatment area such that the actively targeted liposome is critically disrupted thereby releasing the chemotherapeutic drug in the treatment area;
wherein the ultrasound applied to the treatment area comprises a low frequency ultrasound with a power density between about 0.002 W/cm2 and 0.060 W/cm2.